Voss RH - Search Results

1

Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Tan PH, Xue SA, Wei B, Holler A, Voss RH, George AJ. Tan PH, et al. Among authors: voss rh. Mol Med. 2007 Mar-Apr;13(3-4):216-26. doi: 10.2119/2006–00052.Tan. Mol Med. 2007. PMID: 17592557 Free PMC article.

2

Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.

Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ. Xue SA, et al. Among authors: voss rh. Haematologica. 2010 Jan;95(1):126-34. doi: 10.3324/haematol.2009.006486. Epub 2009 Aug 13. Haematologica. 2010. PMID: 19679884 Free PMC article.

3

An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.

Knies D, Klobuch S, Xue SA, Birtel M, Echchannaoui H, Yildiz O, Omokoko T, Guillaume P, Romero P, Stauss H, Sahin U, Herr W, Theobald M, Thomas S, Voss RH. Knies D, et al. Among authors: voss rh. Oncotarget. 2016 Apr 19;7(16):21199-221. doi: 10.18632/oncotarget.8385. Oncotarget. 2016. PMID: 27028870 Free PMC article.

4

Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing.

Xue SA, Chen Y, Voss RH, Kisan V, Wang B, Chen KK, He FQ, Cheng XX, Scolamiero L, Holler A, Gao L, Morris E, Stauss HJ. Xue SA, et al. Among authors: voss rh. Cell Mol Immunol. 2020 Dec;17(12):1275-1277. doi: 10.1038/s41423-020-0396-9. Epub 2020 Mar 17. Cell Mol Immunol. 2020. PMID: 32203185 Free PMC article. No abstract available.

5

Editorial: Translation of genetically engineered T cells in cancer immunotherapy.

Voss RH, Echchannaoui H, Huang H, Xue SA. Voss RH, et al. Front Immunol. 2023 Sep 7;14:1278677. doi: 10.3389/fimmu.2023.1278677. eCollection 2023. Front Immunol. 2023. PMID: 37744369 Free PMC article. No abstract available.

6

Targeting p53, hdm2, and CD19: vaccination and immunologic strategies.

Voss RH, Lotz C, Cellary A, Theobald M. Voss RH, et al. Bone Marrow Transplant. 2000 May;25 Suppl 2:S43-5. doi: 10.1038/sj.bmt.1702353. Bone Marrow Transplant. 2000. PMID: 10933187 Review.

7

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, Stauss HJ, Theobald M. Stanislawski T, et al. Among authors: voss rh. Nat Immunol. 2001 Oct;2(10):962-70. doi: 10.1038/ni1001-962. Nat Immunol. 2001. PMID: 11577350

8

Designing TCR for cancer immunotherapy.

Voss RH, Kuball J, Theobald M. Voss RH, et al. Methods Mol Med. 2005;109:229-56. doi: 10.1385/1-59259-862-5:229. Methods Mol Med. 2005. PMID: 15585925

9

Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.

Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, Strand S, Romero P, Huber C, Sherman LA, Theobald M. Kuball J, et al. Among authors: voss rh. Immunity. 2005 Jan;22(1):117-29. doi: 10.1016/j.immuni.2004.12.005. Immunity. 2005. PMID: 15664164 Free article.

10

Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Voss RH, Kuball J, Engel R, Guillaume P, Romero P, Huber C, Theobald M. Voss RH, et al. Immunol Res. 2006;34(1):67-87. doi: 10.1385/IR:34:1:67. Immunol Res. 2006. PMID: 16720899

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters